Multivariate Analysis of Risk Factors for Metastasis in Retinoblastoma Treated by Enucleation

Joel Kopelman(Armed Forces Institute of Pathology), Saul H. Rosenberg(AbbVie (United States)), Ian W. McLean(Armed Forces Institute of Pathology)

Ophthalmology

April 1, 1987

10.1016/s0161-6420(87)33436-0

Cited by 223

Related Papers

An inhibitor of Bcl-2 family proteins induces regression of solid tumours

|Nature|2005|3.4k

ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets

|Nature Medicine|2013|3k

ABT-263: A Potent and Orally Bioavailable Bcl-2 Family Inhibitor

|Cancer Research|2008|2k

Discovery of a selective catalytic p300/CBP inhibitor that targets lineage-specific tumours

|Nature|2017|853

Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity

|The Lancet Oncology|2010|852